glp-1 for cholesterol Agonists Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH glp 1 and cholesterol GLP-1

Farah T

Collagen deposition increases dramatically

Review the sources used below for this article: This article references information from a study published in the International Dental Journal : Drug-Related Halitosis: A Narrative Review This article references information from The Hershey Company: First Quarter 2026 Earnings Results This article references information from the Kaiser Family Foundation This article references information from a study published in the International Dental Journal: Clinical Practice Guidelines on the Diagnosis and Treatment of Halitosis This article references information from a study published in Gerodontology: A Systematic Review and Meta-Analysis of the Global Prevalence of Dry Mouth in Older Adults This article references information from a study published in Digestion: Pathophysiology of Gastroesophageal Reflux Disease

Who Should Consider Oral vs Injectable?# Oral may be preferred for: Patients with needle phobia or injection anxiety Patients who travel frequently Those seeking lower-cost options Patients comfortable with daily dosing First-line therapy before escalating to injectables Injectable may be preferred for: Patients seeking maximum weight loss Those who prefer less frequent dosing (weekly or monthly) Patients who struggle with daily medication adherence Those who need dual or triple agonist mechanisms Conclusion# The oral GLP-1 revolution is well underway